Q-omics provides the consensus-scored NT5DC3 profile across patient tissues and cancer cell-line models. NT5DC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NT5DC3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NT5DC3 protein abundance shows 25,646 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, KIRC, and LUAD as cancer lineages where NT5DC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NT5DC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NT5DC3 survival associations across molecular data types. NT5DC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NT5DC3 RNA expression–survival associations across cancer types. High NT5DC3 expression shows unfavorable associations in UVM, BLCA, KICH, MESO, LIHC and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NT5DC3 RNA expression.
This table summarizes NT5DC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NT5DC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NT5DC3 shows lower tumor expression in BLCA and higher tumor expression in KIRC, KIRP, LUAD, LUSC and LIHC. The KIRC box plot shows higher NT5DC3 RNA expression in tumor versus normal tissue (log2 FC = +2.122, t-test p < 0.001).
This table shows molecular features associated with NT5DC3 in patient tissues and cancer cell lines. In patient samples, NT5DC3 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NT5DC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
